PuSH - Publication Server of Helmholtz Zentrum München: Activation of peroxisome proliferator-activated receptor-δ as novel therapeutic strategy to prevent in-stent restenosis and stent thrombosis.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Hytönen, J.* ; Leppaenen, O.* ; Braesen, J.H.* ; Schunck, W.H.* ; Müller, D.* ; Jung, F.* ; Mrowietz, C.* ; Jastroch, M. ; von Bergwelt-Baildon, M.* ; Kappert, K.* ; Heuser, A.* ; Drenckhahn, J.D.* ; Pieske, B.* ; Thierfelder, L.* ; Yla-Herttuala, S.* ; Blaschke, F.*

Activation of peroxisome proliferator-activated receptor-δ as novel therapeutic strategy to prevent in-stent restenosis and stent thrombosis.

Arterioscler. Thromb. Vasc. Biol. 36, 1534-1548 (2016)

Publ. Version/Full Text

DOI

PMC

	Free by publisher

Open Access Green as soon as Postprint is submitted to ZB.

Abstract
Metrics
Extra information

OBJECTIVE: Drug-eluting coronary stents reduce restenosis rate and late lumen loss compared with bare-metal stents; however, drug-eluting coronary stents may delay vascular healing and increase late stent thrombosis. The peroxisome proliferator-activated receptor-delta (PPARδ) exhibits actions that could favorably influence outcomes after drug-eluting coronary stents placement. APPROACH AND RESULTS: Here, we report that PPARδ ligand-coated stents strongly reduce the development of neointima and luminal narrowing in a rabbit model of experimental atherosclerosis. Inhibition of inflammatory gene expression and vascular smooth muscle cell (VSMC) proliferation and migration, prevention of thrombocyte activation and aggregation, and proproliferative effects on endothelial cells were identified as key mechanisms for the prevention of restenosis. Using normal and PPARδ-depleted VSMCs, we show that the observed effects of PPARδ ligand GW0742 on VSMCs and thrombocytes are PPARδ receptor dependent. PPARδ ligand treatment induces expression of pyruvate dehydrogenase kinase isozyme 4 and downregulates the glucose transporter 1 in VSMCs, thus impairing the ability of VSMCs to provide the increased energy demands required for growth factor-stimulated proliferation and migration. CONCLUSIONS: In contrast to commonly used drugs for stent coating, PPARδ ligands not only inhibit inflammatory response and proliferation of VSMCs but also prevent thrombocyte activation and support vessel re-endothelialization. Thus, pharmacological PPARδ activation could be a promising novel strategy to improve drug-eluting coronary stents outcomes.

Altmetric

Additional Metrics?

[➜Log in]

Edit extra informations Login

Publication type Article: Journal article

Document type Scientific Article

Corresponding Author

Keywords Blood Platelets ; Coronary Restenosis ; Muscle, Smooth, Vascular ; Peroxisome Proliferator-activated Receptors ; Stents; Vascular Smooth-muscle; Drug-eluting Stents; American-heart-association; Ppar-delta; Cell-proliferation; Growth-factor; Platelet-aggregation; Metabolic Syndrome; Skeletal-muscle; Fatty-acids

ISSN (print) / ISBN 1079-5642

e-ISSN 1524-4636

Journal Arteriosclerosis, Thrombosis, and Vascular Biology

Quellenangaben Volume: 36, Issue: 8, Pages: 1534-1548

Publisher Lippincott Williams & Wilkins

Publishing Place Philadelphia

Non-patent literature Publications

Reviewing status Peer reviewed

Institute(s) Institute of Diabetes and Obesity (IDO)